Amylyx Pharmaceuticals shares are trading lower after the EMA's CHMP adopted a negative opinion on the application for conditional marketing authorization of AMX0035 for amyotrophic lateral sclerosis
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharmaceuticals' shares are trading lower after the EMA's CHMP adopted a negative opinion on the application for conditional marketing authorization of AMX0035 for amyotrophic lateral sclerosis.
June 23, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amylyx Pharmaceuticals' stock price is expected to decline due to the EMA's CHMP negative opinion on the application for conditional marketing authorization of AMX0035 for ALS.
The EMA's CHMP negative opinion on the application for conditional marketing authorization of AMX0035 for ALS directly impacts Amylyx Pharmaceuticals' ability to market the drug in Europe. This is likely to result in a decline in the company's stock price as investors react to the news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100